Ariad Pharmaceuticals (ARIA)

17.53 +0.91  +5.48%  May 21, 5:00PM
Add to Watchlists Create an Alert

Ariad Pharmaceuticals R&D Expense Quarterly:

41.26M for Dec. 31, 2012
View Full Chart

Ariad Pharmaceuticals R&D Expense Quarterly Chart

    Ariad Pharmaceuticals Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 2   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    March 31, 2013 41.26M
    Dec. 31, 2012 37.69M
    Sept. 30, 2012 38.82M
    June 30, 2012 39.42M
    March 31, 2012 28.77M
    Dec. 31, 2011 24.72M
    Sept. 30, 2011 19.69M
    June 30, 2011 18.75M
    March 31, 2011 14.57M
    Dec. 31, 2010 16.17M
    Sept. 30, 2010 13.17M
    June 30, 2010 13.81M
    March 31, 2010 14.84M
    Dec. 31, 2009 15.51M
    Sept. 30, 2009 14.38M
    June 30, 2009 15.81M
    March 31, 2009 17.75M
    Dec. 31, 2008 14.77M
    Sept. 30, 2008 13.36M
    June 30, 2008 11.83M
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
    June 30, 2007 Go Pro
    March 31, 2007 Go Pro
       
    Dec. 31, 2006 Go Pro
    Sept. 30, 2006 Go Pro
    June 30, 2006 Go Pro
    March 31, 2006 Go Pro
    Dec. 31, 2005 Go Pro
    Sept. 30, 2005 Go Pro
    June 30, 2005 Go Pro
    March 31, 2005 Go Pro
    Dec. 31, 2004 Go Pro
    Sept. 30, 2004 Go Pro
    June 30, 2004 Go Pro
    March 31, 2004 Go Pro
    Dec. 31, 2003 Go Pro
    Sept. 30, 2003 Go Pro
    June 30, 2003 Go Pro
    March 31, 2003 Go Pro
    Dec. 31, 2002 Go Pro
    Sept. 30, 2002 Go Pro
    June 30, 2002 Go Pro
    March 31, 2002 Go Pro
    Dec. 31, 2001 Go Pro
    Sept. 30, 2001 Go Pro
    June 30, 2001 Go Pro
    March 31, 2001 Go Pro
    Dec. 31, 2000 Go Pro

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    ARIA R&D Expense Quarterly Benchmarks

    Companies
    Array BioPharma 15.10M
    Celldex Therapeutics 14.09M
    Infinity Pharmaceuticals 40.02M

    ARIA R&D Expense Quarterly Rankings

    Overall 97th percentile
    231 of 8002
    Sector 91st percentile
    57 of 684 in Healthcare
    Industry 93rd percentile
    17 of 248 in Biotechnology

    ARIA R&D Expense Quarterly Range, Past 5 Years

    Minimum 11.83M Jun 2008
    Maximum 41.26M Mar 2013
    Average 21.26M